Ascendis Pharma (ASND) has released an update.
Ascendis Pharma A/S has announced updates to its Articles of Association, detailing the company’s objectives to develop and sell medical disease treatments, and outlining the authorization for various share capital increases through warrants and convertible bonds. The share capital stands at DKK 60,642,144, with provisions allowing the issuance of shares and warrants to key personnel, advisors, and consultants, as well as adjustments to share capital through the board’s discretion.
For further insights into ASND stock, check out TipRanks’ Stock Analysis page.
